DIAMEDICA THERAPEUTICS Insider Options Reveal Confidence in Stroke & Kidney Therapies
Insider option purchases at Diamedica Therapeutics signal executive confidence in its early‑stage stroke and kidney drugs, but investors should weigh the speculative biotech risk and pending Phase III results.
5 minutes to read